<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30196727</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1744-7658</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>27</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Expert opinion on investigational drugs</Title>                <ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation>            </Journal>            <ArticleTitle>Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives.</ArticleTitle>            <Pagination>                <MedlinePgn>787-801</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/13543784.2018.1520838</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">One-third of breast cancer (BC) cases worldwide occur in women aged 65 years and older, with 10 to 15% overexpressing the human epidermal growth factor receptor 2 (HER2). Although several HER2-targeted therapies have been developed, the lack of data regarding their use in older patients hampers evidence-based decision-making for this population. Areas Covered: We review current evidence on the efficacy and safety of HER2-targeted therapies in older adults with BC, focusing on approved therapies such as trastuzumab, lapatinib, pertuzumab, ado-trastuzumab-emtansine, and neratinib. Additionally, we discuss drugs under development to target the HER2-receptor, and to overcome resistance to existing therapies. Finally, we highlight the cardiotoxicity of HER2-targeted drugs among older adults. Expert Opinion: Older adults are underrepresented in trials of HER2-targeted therapies in BC. We propose strategies to increase recruitment of older adults in clinical trials in order to increase the evidence base to treat this growing population.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Soto-Perez-De-Celis</LastName>                    <ForeName>Enrique</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7301-2163</Identifier>                    <AffiliationInfo>                        <Affiliation>a Department of Geriatrics , Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran , Mexico City , Mexico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Loh</LastName>                    <ForeName>Kah Poh</ForeName>                    <Initials>KP</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6978-0418</Identifier>                    <AffiliationInfo>                        <Affiliation>b Division of Hematology/Oncology, Department of Medicine , University of Rochester School of Medicine and Dentistry/James P. Wilmot Cancer Center , Rochester , NY , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Baldini</LastName>                    <ForeName>Capucine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>c Drug Development Department (DITEP) , Gustave Roussy Cancer Campus , Villejuif , France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Battisti</LastName>                    <ForeName>Nicolò Matteo Luca</ForeName>                    <Initials>NML</Initials>                    <AffiliationInfo>                        <Affiliation>d Department of Medicine - Breast Unit , the Royal Marsden NHS Foundation Trust , Sutton , UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chavarri-Guerra</LastName>                    <ForeName>Yanin</ForeName>                    <Initials>Y</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0792-1817</Identifier>                    <AffiliationInfo>                        <Affiliation>e Department of Hemato-Oncology , Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran , Mexico City , Mexico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Glas</LastName>                    <ForeName>Nienke A</ForeName>                    <Initials>NA</Initials>                    <AffiliationInfo>                        <Affiliation>f Department of Surgery , Leiden University Medical Center , Leiden , Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hsu</LastName>                    <ForeName>Tina</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>g Division of Medical Oncology , The Ottawa Hospital Cancer Centre, University of Ottawa , Ottawa , Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hurria</LastName>                    <ForeName>Arti</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7983-9615</Identifier>                    <AffiliationInfo>                        <Affiliation>h Center for Cancer and Aging , City of Hope , Duarte , CA , USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Expert Opin Investig Drugs</MedlineTA>            <NlmUniqueID>9434197</NlmUniqueID>            <ISSNLinking>1354-3784</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HER2 receptor</Keyword>            <Keyword MajorTopicYN="N">ado-trastuzumab emtansine</Keyword>            <Keyword MajorTopicYN="N">breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">cancer vaccines</Keyword>            <Keyword MajorTopicYN="N">cardiotoxicity</Keyword>            <Keyword MajorTopicYN="N">lapatinib</Keyword>            <Keyword MajorTopicYN="N">molecular targeted therapy</Keyword>            <Keyword MajorTopicYN="N">older adults</Keyword>            <Keyword MajorTopicYN="N">pertuzumab</Keyword>            <Keyword MajorTopicYN="N">trastuzumab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30196727</ArticleId>            <ArticleId IdType="doi">10.1080/13543784.2018.1520838</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>